FORE Biotherapeutics today announced that the Company, will participate at the following investor conferences:

• Cantor 2024 Global Healthcare Conference. The Company will attend and participate in one-on-one meetings on Wednesday, September 18.
• UBS 2024 Virtual Biotechnology Private Company Symposium. The Company will attend on Thursday, September 19, and will provide a corporate presentation from 10:00 a.m. – 10:25 a.m. ET.
• Bank of America Healthcare Trailblazers Private Company Conference. The Company will attend and participate in one-on-one meetings on Wednesday, September 25.
• RBC Capital Markets 2024 Virtual Biotechnology Private Company Conference. The Company will attend on Tuesday, October 1, and will sit for a fireside chat from 10:40 a.m. – 11:10 a.m. ET.

Management will host and participate in one-on-one meetings. Please contact Argot Partners to schedule one-on-one meetings with the management team.

About FORE Biotherapeutics

Fore Bio is a precision oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers. The Company’s lead asset plixorafenib (FORE8394; formerly PLX8394) is a V600 and non-V600 BRAF inhibitor with manageable clinical safety and early efficacy signals in an ongoing Phase 1/2a clinical trial. The Fore Bio research and development team is optimizing drug development by identifying existing compounds with known clinical profiles and a clear path through clinical development to advance new medicines for patients without treatment options. For more information, please visit www.fore.bio or follow us on X (formerly Twitter) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240904182093/en/